Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
Total Valuation
Foghorn Therapeutics has a market cap or net worth of $312.61M. The enterprise value is $119.78M.
Market Cap$312.61M
Enterprise Value$119.78M
Share Statistics
Foghorn Therapeutics has 56,529,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding56,529,970
Owned by Insiders1.15%
Owned by Institutions44.91%
Financial Efficiency
Foghorn Therapeutics’s return on equity (ROE) is 1.90 and return on invested capital (ROIC) is -43.67%.
Return on Equity (ROE)1.90
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-43.67%
Return on Capital Employed (ROCE)-0.47
Revenue Per Employee201.80K
Profits Per Employee-773.39K
Employee Count112
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Foghorn Therapeutics is ―. Foghorn Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value-5.69
Price to FCF―
Price to Operating Cash Flow-3.60
PEG Ratio―
Income Statement
In the last 12 months, Foghorn Therapeutics had revenue of 22.60M and earned -86.62M in profits. Earnings per share was -1.58.
Revenue22.60M
Gross Profit22.60M
Operating Income-102.68M
Pretax Income-86.62M
Net Income-86.62M
EBITDA-97.17M
Earnings Per Share (EPS)-1.58
Cash Flow
In the last 12 months, operating cash flow was -90.49M and capital expenditures -838.00K, giving a free cash flow of -91.33M billion.
Operating Cash Flow-90.49M
Free Cash Flow-91.33M
Free Cash Flow per Share-1.62
Dividends & Yields
Foghorn Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.10
52-Week Price Change-29.91%
50-Day Moving Average5.28
200-Day Moving Average5.06
Relative Strength Index (RSI)54.73
Average Volume (3m)107.01K
Important Dates
Foghorn Therapeutics upcoming earnings date is Nov 11, 2025, Before Open (Confirmed).
Last Earnings DateAug 5, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend Date―
Financial Position
Foghorn Therapeutics as a current ratio of 3.73, with Debt / Equity ratio of -30.91%
Current Ratio3.73
Quick Ratio3.73
Debt to Market Cap0.03
Net Debt to EBITDA0.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Foghorn Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Foghorn Therapeutics EV to EBITDA ratio is -2.48, with an EV/FCF ratio of -2.38.
EV to Sales10.65
EV to EBITDA-2.48
EV to Free Cash Flow-2.38
EV to Operating Cash Flow-2.40
Balance Sheet
Foghorn Therapeutics has $199.91M in cash and marketable securities with $23.70M in debt, giving a net cash position of -$176.22M billion.
Cash & Marketable Securities$199.91M
Total Debt$23.70M
Net Cash-$176.22M
Net Cash Per Share-$3.12
Tangible Book Value Per Share-$0.83
Margins
Gross margin is 68.74%, with operating margin of -454.31%, and net profit margin of -383.24%.
Gross Margin68.74%
Operating Margin-454.31%
Pretax Margin-383.24%
Net Profit Margin-383.24%
EBITDA Margin-429.90%
EBIT Margin-443.70%
Analyst Forecast
The average price target for Foghorn Therapeutics is $8.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.50
Price Target Upside53.71% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-31.30%
EPS Growth Forecast36.26%